This clinical trial is focused on studying a type of bone cancer called osteosarcoma, which is considered high-risk. High-risk osteosarcoma can either be metastatic, meaning it has spread to other parts of the body at the time of diagnosis, or it can be localized but shows a poor response to initial treatment. The study is evaluating the effectiveness of a medication called mifamurtide, also known by its code name MEPACT, when used in combination with standard chemotherapy treatments. The chemotherapy medications involved in this study include doxorubicin hydrochloride, ifosfamide, cisplatin, methotrexate, and etoposide.
The purpose of the study is to determine if adding mifamurtide to the usual chemotherapy regimen can improve the outcomes for patients with high-risk osteosarcoma. Participants in the study will receive either the standard chemotherapy alone or the standard chemotherapy combined with mifamurtide. The treatment will be administered over a period of several weeks, and the effects will be monitored to see if the combination helps in preventing the cancer from returning or spreading.
Throughout the study, participants will be closely observed to track their progress and any side effects they may experience. The study aims to provide valuable information on whether the addition of mifamurtide can enhance the effectiveness of chemotherapy in treating high-risk osteosarcoma, potentially leading to better survival rates and outcomes for patients. The trial will continue until the estimated end date in 2033, allowing researchers to gather comprehensive data on the long-term effects and benefits of the treatment.
France 
